A clinical trial to study the effect of Ranolazine for prevention of atrial fibrillation in patients undergoing coronary artery bypass grafting.

Comparison of Ranolazine versus Amiodarone for Prevention of Atrial Fibrillation in Patients with Impaired Left Ventricular Function Undergoing Off Pump Coronary Artery Bypass Grafting - A Randomised Control Trial

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024206

Enrollment

80

Registered

2020-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: Ranolazine: Anti arrhythmic agent- 500 mg for 3 days preoperatively followed by 375 mg BD for 5 days. Route of administration - per oral and total duration of treatment is 8 days. Cont

Sponsors

SRM Medical College Hospital And Research Centre

Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Elective Off pump CABG(OPCAB) Moderate - Severe LV dysfunction(EF

Exclusion criteria

Exclusion criteria: 1.Emergency OPCAB 2.Associated Valvular Heart Lesions 3.Redo surgery 4.Renal dysfunction(creatinine >1.8 mg/dl) 5.Hepatic dysfunction(bilirubin >2 mg/dl)

Design outcomes

Primary

Measure	Time frame
To compare the safety and efficacyTimepoint: 5th post operative day	—

Secondary

Measure	Time frame
To compare the side effectsTimepoint: 6th postoperative day	—

Countries

India

Contacts

Public ContactDrPallavi Deepa Satheesh

SRM Medical College Hospital And Research Centre

kashok_md@yahoo.co.in7358419162

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026